Wednesday, July 2, 2025 7/2/2025

Novel dual-targeted inhibitors of EGFR and aurora kinase for lung cancer

Award Number: R15CA246256
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/08/2021
PERIOD OF PERFORMANCE END DATE: 12/31/2023

Group Awards By:

View Award Description

Novel dual-targeted inhibitors of EGFR and aurora kinase for lung cancer - PROJECT SUMMARY Small molecule EGFR inhibitors constitute the recommended therapy for EGFR-positive non-small cell lung cancer (NSCLC). Resistance was first reported to EGFR inhibitors through mutations in the ATP pocket that was addressed by a new generation of irreversible EGFR inhibitors. However, resistance has continued to evolve with the more recent contributors of resistance being the L858R/T790M/C797S mutations in mEGFR+ NSCLC and mutant KRAS signaling that bypasses EGFR inhibition in mKRAS+ NSCLC. There are currently no viable EGFR-mediated treatments for mKRAS+ NSCLC. Our goal is to develop novel molecules that provide more effective options to treat mKRAS+ and mEGFR+ NSCLC. Aurora kinases (AURK) are mitotic kinases involved in centrosome maturation and separation during mitosis. In addition, aurora kinases drive tumorigenesis and metastasis. Aurora kinase inhibitors have demonstrated improved anticancer effects when used in combination with EGFR inhibitors in both mKRAS+ and mEGFR+ NSCLC. Thus, dual EGFR/AURK inhibition provides a unique approach to overcome resistance to EGFR inhibitors. We have identified novel molecules with dual EGFR/AURK inhibition in our lab. Our compounds demonstrated nanomolar to micromolar potencies against EGFR and AURK. Additionally, our compounds demonstrated preferential inhibition of EGFR and AURK in a 96- kinase selectivity panel. The goal of this proposal is to optimize lead molecules identified in our lab for potent dual EGFR and AURK inhibition that would translate to enhanced antiproliferative effects in mKRAS+ and mEGFR+ NSCLC. In Aim 1, we will synthesize novel series of compounds as analogs of our lead compounds. We will evaluate the compounds in enzymatic assays against EGFR, mutant EGFR and aurora kinases. Solubility will also be assessed. In Aim 2, we will evaluate potent dual EGFR/AURK inhibitors identified from Aim 1 for anticancer effects in mKRAS+ and mEGFR+ NSCLC and toxic effects in normal lung cells. In Aim 3, we will investigate selectivity for dual EGFR/AURK inhibition versus off-target kinases and metabolic stability for potent dual EGFR/AURK inhibitors identified from Aim 2.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	FERRIS STATE UNIVERSITY	1201 S STATE ST	BIG RAPIDS	MI	49307	MECOSTA	USA	Cancer Treatment Research	000	1	5/21/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $377,805 )
2021	2021	FERRIS STATE UNIVERSITY	1201 S STATE ST	BIG RAPIDS	MI	49307	MECOSTA	USA	Cancer Treatment Research	000	1	1/7/2021	NEW	$377,805
														Subtotal = $377,805

Grand Total All Awards = $377,805

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel dual-targeted inhibitors of EGFR and aurora kinase for lung cancer

Award Number: R15CA246256

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/08/2021

PERIOD OF PERFORMANCE END DATE: 12/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer